Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 4/20 | 0.40 |
| ▸ | SI | P14410 | 4/20 | 0.40 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070982 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15215703 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15121661 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15273797 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL2233716 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL24605082 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL1832193 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15273793 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL13509342 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL767128 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3274341-B1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2022-11-02 | — | — | EP | disclosed |
| US-11389466-B2 | Multivalent fucose derivatives for use as a drug | UNIVERSITE DE NANTES (FR) | 2022-07-19 | — | — | US | disclosed |
| EP-3582789-B1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | UNIV NANTES (FR) | 2022-06-22 | — | — | EP | disclosed |
| CN-107531686-B | Inhibitors of pseudomonas aeruginosa LecB | 亥姆霍兹感染研究中心有限责任公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-108495656-B | Antibacterial composition containing deoxyhexose alkyl monoacetal or monoether | 特雷奥斯淀粉及甜味剂比利时公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200281956-A1 | ANTIBACTERIAL COMPOSITION CONTAINING A DEOXYHEXOSE ALKYL MONOACETAL OR MONOETHER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-09-10 | — | — | US | disclosed |
| US-20200268782-A1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | NANTES UNIVERSITE (FR) | 2020-08-27 | — | — | US | disclosed |
| US-10407398-B2 | Inhibitors of Pseudomonas aeruginosa LecB | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-09-10 | — | — | US | disclosed |
| EP-3389731-A1 | ANTIBACTERIAL COMPOSITION CONTAINING A DEOXYHEXOSE ALKYL MONOACETAL OR MONOETHER | Tereos Starch & Sweeteners Belgium (BE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2018149945-A1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | UNIVERSITE DE NANTES (FR) | 2018-08-23 | — | — | WO | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| WO-2002055016-A2 | INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS | RES DEV FOUNDATION (US) | 2002-07-18 | — | — | WO | disclosed |
| US-6358293-B1 | Methods for rendering high concentrations of manganese safe for plant growth and formulations for same | THE HAMPSHIRE CHEMICAL CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| WO-2001038262-A1 | METHODS FOR RENDERING HIGH CONCENTRATIONS OF MANGANESE SAFE FOR PLANT GROWTH AND FORMULATIONS FOR SAME | HAMPSHIRE CHEMICAL CORPORATION (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1027309-A4 | METHODS AND COMPOSITIONS FOR ENHANCING GROWTH OF LIVING ORGANISMS | NONOMURA ARTHUR M (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1027309-A1 | METHODS AND COMPOSITIONS FOR ENHANCING GROWTH OF LIVING ORGANISMS | NONOMURA, Arthur M. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999012868-A1 | METHODS AND COMPOSITIONS FOR ENHANCING GROWTH OF LIVING ORGANISMS | NONOMURA ARTHUR M (US) | 1999-03-18 | — | — | WO | disclosed |
| EP-0275431-B1 | NOVEL ANTHRACYCLINE DERIVATIVES, A PROCESS FOR PREPARING SAME AND THEIR USE AS MEDICAMENTS | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1992-09-23 | — | — | EP | disclosed |
| EP-0275431-A1 | Novel anthracycline derivatives, a process for preparing same and their use as medicaments | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389466-B2 | Multivalent fucose derivatives for use as a drug | FUCA2, FUCA1, FUT6 | M6PR 152/4885MGAM 82/4885SI 1165/4885 |
| US-10407398-B2 | Inhibitors of Pseudomonas aeruginosa LecB | FUCA1, ALG1, FUCA2 | M6PR 470/4885MGAM 185/4885SI 1826/4885 |
| US-20200281956-A1 | ANTIBACTERIAL COMPOSITION CONTAINING A DEOXYHEXOSE ALKYL MONOACETAL OR MONOETHER | DPM1, GNE, DERA | M6PR 270/4885MGAM 11/4885SI 378/4885 |
| US-20200268782-A1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | FUCA2, FUCA1, FUT6 | M6PR 152/4885MGAM 82/4885SI 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.